Sanofi SA (SNY) Stock AnalysisSNYSanofi SA

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sanofi SA (SNY) is a good buy right now, trading at $40.61, with a forward P/E of 8.59, indicating strong valuation potential. The recent partnership expansion with Regeneron, which includes a $1 billion upfront payment, enhances its growth prospects significantly. However, the main risk is the recent downgrade by Morgan Stanley, lowering the price target to $49, which suggests potential downside.

3 analysts cover SNY: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 79.36.